bsg005
Small moleculeexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 31, 2021 (NCT04921254)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06678113 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2024 | Alkem Labs Ltd, Biosergen AS |
| NCT04921254 | Phase 1 | Aug 31, 2021 | Biosergen AS, Greenlight Clinical, Nucleus Network Ltd, Select Pharma Pty Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biosergen AS | For profit | 2 | 2 | 2 | 2021 |
| Alkem Labs Ltd | For profit | 1 | 0 | 1 | 2024 |
| Greenlight Clinical | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2021 |
| Select Pharma Pty Ltd | For profit | 1 | 0 | 1 | 2021 |
5 organizations
Page 1 / 1